A Phase II Trial of Regadenoson in Sickle Cell Anemia

This study is currently recruiting participants.
Verified November 2013 by Dana-Farber Cancer Institute
Sponsor:
Collaborators:
Brigham and Women's Hospital
Children's Hospital Boston
LaJolla Institute for Allergy and Immunology
Washington University School of Medicine
Children's Hospital Medical Center, Cincinnati
University of Illinois at Chicago
Medical College of Wisconsin
Duke University
Information provided by (Responsible Party):
David G. Nathan, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01788631
First received: February 7, 2013
Last updated: November 13, 2013
Last verified: November 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)